Navigation Links
Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Date:7/11/2011

itive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results may be obtained in 2012, it was decided to enroll an additional 100 patients early in 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for Herceptin.  Although 75% of breast cancer patients have some level of HER-2 expression and are eligible for AE37, only 25% have HER-2 levels high enough to be eligible for Herceptin.  The population of patients with low-to-intermediate levels of HER-2 expression currently has no treatment option.  For this reason, it is anticipated that a Phase III trial will be conducted in this specific patient population having low-to-intermediate HER-2 expression levels.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows f
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
2. Generex Provides Clarification of Facts
3. Generex Announces Results of Annual Stockholders Meeting
4. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
5. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
6. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
7. Generex Announces $3.0 Million Capital Investment
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
10. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
11. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... ME (PRWEB) December 18, 2014 Ed ... director of the Center for Excellence in the Neurosciences ... New England, has been selected as a member of ... is the first neuroscientist from Maine to receive this ... nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... , Dec. 18, 2014   ISN ... & Safety Performance Indicators publication series. With ... of activity reported in 2013 within its online contractor ... and safety key performance indicator (KPI) statistics. ... Clients, U.S. publication is available in two ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 “Never ... at Philipps- Universität Marburg’s Department of Physics, advises ... in the newly released SPIE Women in ... be too shy to ask questions.” , In ... engineering, and mathematics) occupations ranging from university professor ...
Breaking Biology Technology:UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... Exelixis,Inc. (Nasdaq: EXEL ) announced earlier today ... Deerfield Management. The arrangement will,be discussed by Exelixis management ... ET today, Thursday, June 5. To listen to a ... Investors at, http://www.exelixis.com ., A replay of the ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced that ... B Decoy (NF-kB Decoy) program, which includes the,clinical ... NF-kB Transcription Factor Decoy inhibits NF-kappa B, a ... as inflammatory,bowel disease (IBD), eczema, rheumatoid arthritis, and ...
... Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... Annual Global Healthcare Conference on Tuesday,June 10, at ... a live,webcast of the presentation on our website ... recommended that listeners log on 15 minutes early ...
Cached Biology Technology:Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 2Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program 3
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... next generation of treatments for shock or stroke could be ... ?neuroglobin. In a review article to be published in the ... Rome describe this protein, which may be the key to ... for patients. , The Italian researchers suggest that neuroglobin is ...
... be used to return severely failing hearts to their ... according to new research. , The mechanical devices, known ... in patients with very severe heart failure whilst they ... England Journal of Medicine, shows that using an LVAD ...
... will fund a 5-year study examining why dead zones have ... allow them to detect the cause and stop the spread ... is a very serious problem," said University of Michigan's Donald ... and lead investigator of the project. "In the 1960s and ...
Cached Biology News:Mechanical 'artificial hearts' can remove need for heart transplant by returning heart to normal 2Researchers to study why dead zone returned to Lake Erie 2
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
anti-achaete...
... Super-Sensitive, Super-Dark, Super-Small! ... with the ChemiDoc-It Imaging System. High-sensitivity ... produces low-background noise and wide dynamic ... a short exposure time. The light-tight ...
... Based Oligonucleotide) Genome Set and MEEBO (Mouse ... contain a collection of open source oligo ... allowing interrogation of thousands of genes. Developed ... University and UCSF, the sets enable the ...
Biology Products: